Sclerostin promotes human dental pulp cells senescence

Yanjing Ou 1, Yi Zhou 1, Shanshan Liang Corresponding Author 1, Yining Wang Corresponding Author 1

1 The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China

Corresponding Authors: Shanshan Liang, Yining Wang
Email address: wb000867@whu.edu.cn, wang.yn@whu.edu.cn

Background. Senescence-related impairment of proliferation and differentiation limits the use of dental pulp cells for tissue regeneration. Deletion of sclerostin improves the dentinogenesis regeneration, while its role in dental pulp senescence is unclear. We investigated the role of sclerostin in subculture-induced senescence of human dental pulp cells (HDPCs) and in the senescence-related decline of proliferation and odontoblastic differentiation. Methods. Immunohistochemical staining and qRT-PCR analyses were performed to examine the expression pattern of sclerostin in young (20- to 30-year-old) and senescent (45- to 80-year-old) dental pulps. HDPCs were serially subcultured until senescence, and the expression of sclerostin was examined by qRT-PCR analysis. HDPCs with sclerostin overexpression and knockdown were constructed to investigate the role of sclerostin in HDPCs senescence and senescence-related impairment of odontoblastic differentiation potential. Results. By immunohistochemistry and qRT-PCR, we found a significantly increased expression level of sclerostin in senescent human dental pulp compared with that of young human dental pulp. Additionally, elevated sclerostin expression was found in subculture-induced senescent HDPCs in vitro. By sclerostin overexpression and knockdown, we found that sclerostin promoted HDPCs senescence-related decline of proliferation and odontoblastic differentiation potential with increased expression of p16, p53 and p21 and downregulation of the Wnt signaling pathway. Discussion. The increased expression of sclerostin is responsible for the decline of proliferation and odontoblastic differentiation potential of HDPCs during cellular senescence. Anti-sclerostin treatment may be beneficial for the maintenance of the proliferation and odontoblastic differentiation potentials of HDPCs.
Title: Sclerostin promotes human dental pulp cells senescence

Yanjing Ou¹, Yi Zhou¹, Shanshan Liang¹, Yining Wang¹

¹ The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, China.

Corresponding authors:
Shanshan Liang and Yining Wang

E-mail: wb000867@whu.edu.cn and wang.yn@whu.edu.cn
Abstract

Background. Senescence-related impairment of proliferation and differentiation limits the use of dental pulp cells for tissue regeneration. Deletion of sclerostin improves the dentinogenesis regeneration, while its role in dental pulp senescence is unclear. We investigated the role of sclerostin in subculture-induced senescence of human dental pulp cells (HDPCs) and in the senescence-related decline of proliferation and odontoblastic differentiation.

Methods. Immunohistochemical staining and qRT-PCR analyses were performed to examine the expression pattern of sclerostin in young (20- to 30-year-old) and senescent (45- to 80-year-old) dental pulps. HDPCs were serially subcultured until senescence, and the expression of sclerostin was examined by qRT-PCR analysis. HDPCs with sclerostin overexpression and knockdown were constructed to investigate the role of sclerostin in HDPCs senescence and senescence-related impairment of odontoblastic differentiation potential.

Results. By immunohistochemistry and qRT-PCR, we found a significantly increased expression level of sclerostin in senescent human dental pulp compared with that of young human dental pulp. Additionally, elevated sclerostin expression was found in subculture-induced senescent HDPCs in vitro. By sclerostin overexpression and knockdown, we found that sclerostin promoted HDPCs senescence-related decline of proliferation and odontoblastic differentiation potential with increased expression of p16, p53 and p21 and downregulation of the Wnt signaling pathway.

Discussion. The increased expression of sclerostin is responsible for the decline of proliferation and odontoblastic differentiation potential of HDPCs during cellular senescence. Anti-sclerostin
treatment may be beneficial for the maintenance of the proliferation and odontoblastic
differentiation potentials of HDPCs.

**Introduction**

Dental caries, trauma, abrasion, attrition, erosion and dental treatment lead to tooth tissues
destruction, which eventually results in tooth loss. Non-biological treatment strategies for tooth
loss, such as bridges, dentures, and implants, may fit poorly or induce foreign body reaction and
run the risk of rejection by immune system (Modino & Sharpe, 2005; Yen & Sharpe, 2006).
Dental pulp cells (DPCs), a heterogeneous population of odontoblasts, epithelia, neurocytes, and
mesenchymal cells, possess self-renewal and pluripotent differentiation potentials and play a
crucial role in maintaining dental pulp homeostasis (Gronthos et al., 2002; Iohara et al., 2004).
Engineering tissue regeneration using DPCs as seed cells is a useful strategy to regenerate the
dentin-pulp complex, thereby lengthening the lifespan of teeth by preserving their defensive
ability (Gronthos et al., 2002; Karaoz et al., 2011; Potdar & Jethmalani, 2015; Simon et al.,
2011).

In an aging society, fibrosis, atrophy, loss of cellularity, and degeneration of odontoblasts caused
by aging make it more difficult to maintain dental health of older individuals (Nakashima &
Iohara, 2014). DPC senescence, caused by aging or other cytotoxic factors (e.g., oxidative stress
due to oral procedures (Soares et al., 2015) and irradiation (Muthna et al., 2010)), is a state of
irreversible cellular arrest accompanied by aggregation of intracellular senescence molecules p16
and p53 (Rayess, Wang & Srivatsan, 2012), and changes in secretion of bioactive soluble factors,
which lead to the decreased and then the arrest of proliferation and differentiation potentials
(Iohara et al., 2014). However, little is known about the mechanisms underlying DPC senescence. Previous studies demonstrated that several intracellular factors including p16, p21 and Bmi-1 are involved in the progress of DPC senescence (Choi et al., 2012; Egbuniwe et al., 2011; Mehrazarin et al., 2011). Recently, it was reported that the properties of senescent cells can be reversed by changing the extrinsic microenvironment (Wagner et al., 2008; Nakashima & Iohara, 2014). Therefore, identifying specific extrinsic factors involved in DPC senescence is of great importance to biologically based tissue regeneration.

Sclerostin is a 190-amino acid secreted glycoprotein encoded by the *SOST* gene. Its expression is restricted to the great arteries (Zhou et al., 2017), osteocytes (Compton & Lee, 2014), chondrocytes (Chan et al., 2011), and cementocytes (Bao et al., 2013). The deletion or down-regulation of sclerostin causes high bone mass diseases such as sclerosteosis (van Lierop et al., 2011) and Van Buchem disease (Loots et al., 2005). As a well-known negative regulator of bone formation (Zhang et al., 2016), sclerostin inhibits the proliferation and differentiation of cementoblasts (Bao et al., 2013) and osteoprogenitor cells including osteosarcoma cells (Zou, Zhang & Li, 2017) and human mesenchymal stem cells (Sutherland et al., 2004). Recently, significantly elevated serum sclerostin was shown in the elderly (Modder et al., 2011; Roforth et al., 2014), suggesting a possible role of sclerostin in aging-related bone loss as a result of decreased regenerative potential caused by the accumulation of senescent cells (Farr et al., 2017). In addition, previous studies demonstrated that the increased sclerostin produced by osteoclasts from aged mice led to reduced bone formation (Ota et al., 2013), and anti-sclerostin treatment increased bone mass in aged rats (Li et al., 2009). Moreover, the activator of Sirt1, a
critical regulator of aging and longevity (Satoh et al., 2013), rescued ovariectomy-induced bone loss by decreasing sclerostin expression (Artsi et al., 2014). Therefore, it was speculated that sclerostin might impact cellular senescence in terms of differentiation and proliferation.

Similar to the higher level of sclerostin in aged individuals, the expression level of sclerostin varies in embryonic and adult mouse incisors and molars (Naka & Yokose, 2011), indicating a possible role of sclerostin in DPC senescence. Additionally, Collignon et al. found that sclerostin deficiency increased reparative dentinogenesis in mice (Collignon et al., 2017), implying anti-sclerostin might reverse the decreased regenerative potential of aged dental pulp. Taken together, we hypothesized a possible correlation between sclerostin and DPC senescence. Therefore, the purpose of our study was to elucidate the role of sclerostin in the process of human dental pulp cell (HDPC) senescence as well as aging-related impairment of HDPC proliferation and odontoblastic differentiation.

**Materials and Methods**

This work was carried out in accordance with the World Medical Association Declaration of Helsinki (World Medical, 2013). The protocols and procedures were reviewed and approved by the Ethical Committee of the School and Hospital of Stomatology, Wuhan University, China (2015C12).

**Human dental pulp collection**

Healthy and fresh human premolars were extracted from 20- to 80-year-old patients who were under orthodontic or periodontal treatment in the Hospital of Stomatology, Wuhan University. All donors gave their informed consent. The teeth were divided into two groups: the young group
contained 30 teeth from 20- to 30-year-old patients and the old group contained 20 teeth from 45- to 80-year-old patients.

Ten teeth from each group were used for immunohistochemical analysis, and ten teeth from each group for qRT-PCR analysis. The remaining 10 teeth from the young group were used for HDPC culture.

**Immunohistochemical analysis**

Teeth were fixed with 4% paraformaldehyde at room temperature and decalcified in 10% EDTA solution for more than 6 months. Teeth were cut into 5-μm-thick serial sections, which were collected on poly-L-lysine-coated slides. For immunohistochemical staining, the sections were dewaxed and incubated with rabbit anti-sclerostin (1:200; Abclonal, Boston, USA) at 4°C overnight. The staining was performed using a biotin-streptavidin kit (ZhongShan Biotech, Beijing, China) before the sections were counterstained with hematoxylin.

**Real-time PCR analysis**

Total RNA was isolated using the RNAiso kit (Takara, Japan). First-strand cDNA syntheses were performed by using the PrimeScript™ RT reagent Kit with gDNA Eraser (Takara). Real-time polymerase chain reaction for sclerostin, p16, p53, p21, alkaline phosphatase (ALP), osteocalcin (OCN), osteocalcin (OPN), dentin sialophosphoprotein (DSPP) and glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) was performed with the SYBR Green Kit (Takara) using a Applied BioSystems 7900HT thermocycler (Applied Biosystems, CA. USA). The primers are listed in Table 1. The relative amount or fold change of the target gene was normalized relative to the level of human GAPDH and the control groups.
Cells and cell culture

HDPCs were isolated from the healthy dental pulp of 10 premolars from young group. The dental pulp tissues were digested in a solution containing 4 mg/mL dispase and 3 mg/mL collagenase type I for 1 hour at 37°C and then cultured in α-modified essential medium (α-MEM; HyClone Laboratories, Inc, UT, USA) containing 10% fetal bovine serum (FBS; Gibco, NY, USA) at 37°C under 5% CO₂. Confluent monolayers were dissociated with 0.5% (w/v) trypsin-EDTA for subculture. HDPCs were serially subcultured until the cells spontaneously arrested their replication. In brief, $2 \times 10^5$ HDPCs were plated in 60 mm diameter dishes and the medium was changed every 3 days. When the cells reach 80% confluence, all cells were dissociated with 0.5% (w/v) trypsin-EDTA and counted by a cell counting device (Vi-CELL™ XR, Beckman Coulter, CA, USA). The number of population doublings (PD) was calculated using the following formula: $PD = \log_2 (\text{cells harvested/cells seeded}) + \text{previous PD}$ (Huh et al., 2016; Kitajima et al., 2011). For odontoblastic induction, the medium was changed to the odontoblastic induction medium, containing α-MEM, 5% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 10 mmol/L β-glycerophosphate, 50 μg/mL ascorbic acid, and 10 nmol/L dexamethasone (Sigma-Aldrich Co, MO, USA). Cultures were maintained with a medium change every 3 days.

Lentivirus packaging and cell infection

Full human SOST cds sequence and a human SOST sh-RNA were cloned and inserted into the PCDH-CMV-MCS-EF1-copGFP vector (GenePharma, China) and the GV298 vector (Genechem, China), respectively. Lentiviral particles were produced using three-plasmid systems, including pMD2.G, psPAX2 and the individual vectors, with NEOFECT™ DNA transfection reagent (Neofect, China) according to the manufacturer’s instruction. For infection, HDPCs were
incubated with lentiviral particles and polybrene (4 μg/mL) in complete medium for 12 hours.

Cells with successful infection by pCDH-human-SOST were designated SOST, cells infected by sh-SOST were designated sh-SOST, and control cells infected by empty vector were designated Control and sh-Ctrl, respectively. The expression of sclerostin was quantified by real-time PCR and Western blot analysis. The mRNA and protein expression levels were significantly upregulated in the SOST group ($P < 0.001$, Fig. 1E and F), while they were knocked down by over 85% in the sh-SOST group 48 hours after infection ($P < 0.0001$, Fig. 1G and H).

**Western blot**

Cells were lysed in M-PER Mammalian Protein Extraction Reagent (Thermo, IL, USA) combined with a cocktail of protease inhibitors (Roche Molecular Biochemicals, Rotkreuz, Switzerland). Total lysate was loaded and separated by SDS/PAGE. Primary antibodies specific for sclerostin (1:1000, Abclonal), phosphor-β-catenin (p-β-catenin) (1:1000, Cell Signaling Technology, MA, USA), and β-actin (1:5000, Santa Cruz, CA, USA) were used.

**Senescence-associated β-galactosidase assay (SA-β-Gal)**

To determine senescence of HDPCs, an SA-β-Gal kit (Beyotime, China) was used according to the manufacturer’s instructions. In brief, cells seeded on slips were fixed with paraformaldehyde and incubated with SA-β-Gal overnight. Senescent HDPCs were identified by blue-staining under standard light microscopy.

**Cell proliferation assay**

HDPCs were seeded at a density of $2 \times 10^3$ cells/well in a 96-well plate and cultured for 24 hours, and then the medium was replaced with fresh medium. On days 1, 2, 3, and 4, the density of
viable cells within each well was quantified with the Cell Counting Kit-8 (CCK-8; Dojindo, Japan) according to the manufacturer’s protocols. The absorbance at 450 nm was measured to calculate the number of viable cells in each well. A well with medium and CCK-8 solution but without cells was used as the baseline.

**Alkaline phosphatase staining and ALP activity assay**

ALP staining was performed according to the manufacturer’s instructions (Beyotime). For ALP activity, cells were lysed with 0.1% Triton X-100, and 50 μL lysate was mixed with 100 μL p-nitrophenyl phosphate (4mg/mL). The mixture was incubated at 37 °C for 15–20 minutes. The reaction was stopped by the addition of 0.5 N NaOH (100 μL) and read spectrophotometrically at 405 nm. The protein concentration of the lysate was determined as described in the manufacturer’s instructions of the Pierce BCA protein assay kit (Thermo). The enzyme activity was quantified by a p-nitrophenol standard curve and normalized by protein concentration.

**Alizarin red staining**

Cells were cultured in 12-well cell culture dishes in the odontoblastic induction medium for 14 days. Then, cells were fixed with 4% paraformaldehyde and stained with 2% alizarin red. The stain was desorbed with 10% cetylpyridinium chloride for 1 hour and the absorbance was examined at 562 nm.

**Statistical analysis**

All experiments were repeated at least three times. Quantitative results are expressed as the mean ± standard deviation. Data were analyzed by t-test and one-way analyses of variance using SPSS 19.0 software (SPSS Inc, IL, USA). P values <0.05 were considered statistically significant.
Results

Expression of sclerostin is increased in senescent human dental pulp and subculture-induced senescent HDPCs

The immunohistochemistry assay showed that the expression of sclerostin in young human pulp was very low, and positive sclerostin staining was only found in odontoblasts of young dental pulp. In contrast, strong staining of sclerostin was observed throughout the senescent human dental pulp, especially in the odontoblasts lining near the pre-dentin (Figure 1A and B). Similarly, qRT-PCR analyses showed a higher expression level of sclerostin mRNA in senescent dental pulp, along with increased expression levels of p16, p53, and p21 (Figure 1C).

Rapidly proliferating HDPCs were serially subcultured until the cells spontaneously arrested replication. HDPCs completing 16 and 54 population doublings (PDs) were defined as young and senescent HDPCs, respectively (Mehrazarin et al., 2011). In line with the higher expression levels of sclerostin, p16, p53, and p21 in senescent dental pulp, qRT-PCR analyses showed significantly higher expression levels of sclerostin, p16, p53, and p21 in senescent HDPCs (Figure 1D).

Sclerostin induces HDPCs senescence

To access the role of sclerostin in senescence of HDPCs, sclerostin was overexpressed in early-passaged HDPCs. As shown in Figure 2, sclerostin overexpression significantly increased the number of SA-β-Gal-positive cells. In addition, the CCK-8 assay showed significantly decreased proliferation and higher expression levels of p16, p53, and p21 in sclerostin-overexpressing HDPCs (Figure 2C and D). In contrast, knockdown of sclerostin in late-passaged HDPCs
showed fewer SA-β-Gal-positive cells, increased proliferation, and decreased p16, p53 and p21 expressions (Figure 2E–H). In conclusion, these results suggest that sclerostin induces HDPCs senescence and inhibits HDPCs proliferation via the p16 and p53 signaling pathways.

**Sclerostin inhibits odontoblastic differentiation of HDPCs**

To determine the effect of sclerostin on HDPC differentiation, we compared the odontoblastic differentiation ability between early-passaged SOST and Control groups. As shown in Figure 3, sclerostin overexpression significantly decreased the odontoblastic differentiation of early-passaged HDPCs as shown by the decreased mineralization nodules formation and a decline in ALP activity along with lower expression levels of odontoblastic differentiation markers such as ALP, OPN, CON, and DSPP (Figure 3A-C). Moreover, knockdown of sclerostin rescued the decreased odontoblastic differentiation of senescent HDPCs (Figure 3D–E). These data imply that the increased expression of sclerostin contributed to the impaired odontoblastic differentiation potential of senescent HDPCs.

**The Wnt/β-catenin pathway may be involved in the progress of HDPCs senescence related to higher expression of sclerostin**

To clarify the mechanisms underlying sclerostin-related HDPCs senescence, we examined the Wnt/β-catenin pathway activity. Western blot analysis showed that overexpression of sclerostin suppressed the activity of the Wnt/β-catenin pathway by increasing the expression of p-β-catenin and sclerostin knockdown significantly increased the activity of the Wnt/β-catenin pathway (Figure 4). These results suggest that sclerostin might accelerate senescence of HDPCs in a Wnt signaling pathway-dependent mechanism.
The importance of dental pulp cells in diverse therapeutic application has been increasingly recognized in recent years. However, the impairment of proliferation and differentiation caused by cellular senescence restricts their application in tissue regeneration. So far, little is known about the progress of HDPC senescence. Herein, by sclerostin overexpression in early-passaged HDPCs and knockdown in late-passaged HDPCs, we showed that sclerostin knockdown is beneficial for the maintenance of the proliferation and odontoblastic differentiation potentials of HDPCs during cellular senescence.

In the present study, we found that there was a significantly higher expression of sclerostin in senescent human dental pulp tissues and senescent HDPCs. These data are consistent with the findings that serum sclerostin levels increase with age, which may contribute to age related bone loss (Modder et al., 2011; Zhang et al., 2016). While noteworthy, these results do not provide causality. Therefore, SA-β-Gal staining, a biomarker of cellular senescence (Debacq-Chainiaux et al., 2009), was performed in early-passaged HDPCs with sclerostin overexpression and in late-passaged HDPCs with sclerostin knockdown to determine whether the higher expression of sclerostin was the cause of HDPC senescence or not. Sclerostin overexpression accelerated HDPC senescence and sclerostin knockdown decreased senescence of HDPCs in vitro. To the best of our knowledge, it was the first study confirming the exact role of sclerostin in cellular senescence. Well-designed studies are now required to determine the role of sclerostin in HDPC senescence in vivo and to identify whether this promoting effect of sclerostin on HDPC senescence is universal in other cells or is cell-type specific.

Senescence of cells is mostly due to activation of G1/S cell cycle arrest proteins (Itahana, Campisi & Dimri, 2004). The p53/p21 and p16/retinoblastoma axes are two important pathways
in cellular senescence. The p16 protein mediates cell cycle arrest by inhibiting DNA replication 
via preventing phosphorylation of the retinoblastoma protein (Rayess, Wang & Srivatsan, 2012). 
The p53-mediated response to DNA damage, oxidants and hypoxia induces the expression of 
p21, leading to cellular senescence by inhibiting the activity of cyclin dependent kinases 
(Muthna et al., 2010; Tonnessen-Murray, Lozano & Jackson, 2017). Our study showed that 
senescent human dental pulp and subculture-induced senescent HDPCs exhibited higher 
expression levels of p16, p53 and p21. These data are in accordance with previous findings that 
p16, p53 and p21 are highly expressed in senescent dental pulp cells (Mas-Bargues et al., 2017; 
Muthna et al., 2010). Conversely, downregulation of p53-p21 decreased senescence of dental 
pulp stem cells (Choi et al., 2012). Meanwhile, p16 knockdown significantly reduced 
senescence-related dysfunction of dental pulp mesenchymal stem cells (Feng et al., 2014). 
Inspired by the similar expression profile of p16, p53, p21 and sclerostin during HDPCs 
senescence, we examined the effect of sclerostin on the expression of p16, p53 and p21 in 
HDPCs. Sclerostin overexpression significantly increased the expression levels of p16, p53 and 
p21, whereas, sclerostin knockdown decreased the expression levels of p16, p53 and p21. 
Although, there had previously been no reports about the effect of sclerostin on the expression of 
p16, p53 and p21, it was believed that senescence acted as a tumor suppressor and sclerostin 
silence significantly increased the proliferation of osteosarcoma cells by promoting the progress 
of cell cycle in G1/S phase (Zou, Zhang & Li, 2017). Thus, one can conclude that sclerostin may 
modulate the progression of HDPC senescence via both the p16 and p53 pathways. 
Odontoblastic differentiation potential was impaired in senescent HDPCs with decreased 
expression levels of odontoblastic differentiation markers ALP, OCN, OPN and DSPP, which 
play key roles in matrix formation and calcification initialization in bone and teeth (Bae et al.,
In this study, we found that sclerostin significantly inhibited odontoblastic differentiation of early-passaged HDPCs with downregulation of odontoblastic markers ALP, OCN, OPN, and DSPP. Furthermore, knockdown of sclerostin increased odontoblastic differentiation of subculture-induced senescent HDPCs with higher expression levels of these odontoblastic differentiation markers. These results are in line with the finding that mice dental pulp cells with sclerostin deficiency exhibited enhanced in vitro mineralization (Mehrazarin et al., 2011). These results indicate that the increased expression of sclerostin was responsible for impairment of odontoblastic differentiation potential in senescent HDPCs.

It was reported that sclerostin efficiently inhibited Wnt signaling by interrupting the Wnt-Frizzled-LRP5/6 receptor complex via binding with the Wnt co-receptor LRP5/6 (Semenov, Tamai & Xi, 2005), leading to upregulated expression of p-β-catenin, thereby preventing the nucleus translocation of stabilized β-catenin and thus downregulating downstream genes expression (Bae et al., 2015). Wnt signaling plays an essential role in age-related changes in stem cells. Previous studies found that inhibiting Wnt signaling initiated senescence of glioblastoma cells and human WI38 fibroblasts (Lambiv et al., 2011; Ye et al., 2007). Furthermore, Wnt1, an agonist of Wnt signaling, rescued the impaired neurogenic differentiation potential of aged dental pulp stem cells (Feng et al., 2013). In this study, sclerostin overexpression attenuated the activity of Wnt signaling and sclerostin knockdown activated Wnt signaling. These results indicate that sclerostin might accelerate senescence of HDPCs, in part, by decreasing Wnt signaling. However, the exact mechanism of sclerostin-related HDPC senescence requires further study to elucidate.

**Conclusion**
Taken together, the higher expression of sclerostin might accelerate HDPC senescence and was responsible for the attenuated proliferative and odontoblastic differentiation potentials in senescent HDPCs via p16 and p53 pathways. Sclerostin may serve as a target to delay the progress of HDPCs senescence.

Acknowledgements

We thank M.D.S. Chufang Liao (School and Hospital of Stomatology, Wuhan University) and M.D.S. Yun Wu (School and Hospital of Stomatology, Wuhan University) for HDPC preparation and for their advice on our work.

References

Artsi H, Cohen-Kfir E, Gurt I, Shahar R, Bajayo A, Kalish N, Bellido TM, Gabet Y, Dresner-Pollak R. 2014. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. *Endocrinology* 155:3508-3515 DOI: 10.1210/en.2014-1334.

Bae CH, Kim TH, Ko SO, Lee JC, Yang X, Cho ES. 2015. Wntless regulates dentin apposition and root elongation in the mandibular molar. *Journal of Dental Research* 94:439-445 DOI: 10.1177/0022034514567198.

Bao XF, Liu YY, Han GH, Zuo ZG, Hu M. 2013. The effect on proliferation and differentiation of cementoblast by using sclerostin as inhibitor. *International Journal of Molecular Sciences* 14:21140-21152 DOI:10.3390/ijms141021140.

Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, Cake MA, Read RA, Bateman JF, Sambrook PN, Little CB. 2011. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. *Osteoarthritis Cartilage* 19:874-885 DOI: 10.1016/j.joca.2011.04.014.
Chen S, Rani S, Wu YM, Unterbrink A, Gu TT, Gluhak-Heinrich J, Chuang HH, MacDougall M. 2005. Differential regulation of dentin sialophosphoprotein expression by Runx2 during odontoblast cytodifferentiation. *Journal of Biological Chemistry* 280:29717-29727 DOI: 10.1074/jbc.M502929200.

Choi YJ, Lee JY, Chung CP, Park YJ. 2012. Cell-penetrating superoxide dismutase attenuates oxidative stress-induced senescence by regulating the p53-p21(Cip1) pathway and restores osteoblastic differentiation in human dental pulp stem cells. *International Journal of Nanomedicine* 7:5091-5106 DOI: 10.2147/IJN.S31723.

Collignon AM, Amri N, Lesieur J, Sadoine J, Ribes S, Menashi S, Simon S, Berdal A, Rochefort GY, Chau ssain C, Gaucher C. 2017. Sclerostin deficiency promotes reparative dentinogenesis. *Journal of Dental Research* 96:815-821 DOI: 10.1177/0022034517698104.

Compton JT, Lee FY. 2014. A review of osteocyte function and the emerging importance of sclerostin. *Journal of Bone and Joint Surgery* 96:1659-1668 DOI: 10.2106/JBJS.M.01096.

Debacq-Chainiaux F, Erusalimsky JD, Campisi J, Toussaint O. 2009. Protocols to detect senescence-associated beta-galactosidase (SA-betagal) activity, a biomarker of senescent cells in culture and in vivo. *Nature Protocols* 4:1798-1806 DOI: 10.1038/nprot.2009.191.

Farr JN, Xu M, Weivoda MM, Monroe DG, Fraser DG, Onken JL, Negley BA, Sfeir JG, Ogrodnik MB, Hachfeld CM, LeBrasseur NK, Drake MT, Pignolo RJ, Pirtskhalava T, Tchkonia T, Oursler MJ, Kirkland JL, Khosla S. 2017. Targeting cellular senescence prevents age-related bone loss in mice. *Nature Medicine* 23:1072-1079 DOI: 10.1038/nm.4385.

Feng XM, Xing J, Feng GJ, Huang D, Lu XH, Liu SZ, Tan W, Li LR, Gu ZF. 2014. p16(INK4A) mediates age-related changes in mesenchymal stem cells derived from human dental pulp.
through the DNA damage and stress response. *Mechanisms of Ageing and Development* 141:46-55 DOI: 10.1016/j.mad.2014.09.004.

Feng XM, Xing J, Feng GJ, Sang AM, Shen BY, Xu Y, Jiang JX, Liu SZ, Tan W, Gu ZF, Li LR. 2013. Age-dependent impaired neurogenic differentiation capacity of dental stem cell is associated with Wnt/β-catenin signaling. *Cellular and Molecular Neurobiology* 33:1023-1031 DOI: 10.1007/s10571-013-9965-0.

Gronthos S, Brahim J, Li W, Fisher LW, Cherman N, Boyde A, DenBesten P, Robey PG, Shi S. 2002. Stem cell properties of human dental pulp stem cells. *Journal of Dental Research* 81:531-535 DOI: 10.1177/154405910208100806.

Huh CJ, Zhang B, Victor MB, Dahiya S, Batista LF, Horvath S, Yoo AS. 2016. Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. *Elife* 5: e18648 DOI: 10.7554/eLife.18648.

Iohara K, Nakashima M, Ito M, Ishikawa M, Nakasima A, Akamine A. 2004. Dentin regeneration by dental pulp stem cell therapy with recombinant human bone morphogenetic protein 2. *Journal of Dental Research* 83:590-595 DOI: 10.1177/154405910408300802.

Iohara K, Murakami M, Nakata K, Nakashima M. 2014. Age-dependent decline in dental pulp regeneration after pulpectomy in dogs. *Experimental Gerontology* 52: 39-45 DOI: 10.1016/j.exger.2014.01.020.

Itahana K, Campisi J, Dimri GP. 2004. Mechanisms of cellular senescence in human and mouse cells. *Biogerontology* 5:1-10 DOI: 10.1023/B:BGEN.0000017682.96395.10.

Karaoz E, Demircan PC, Saglam O, Aksoy A, Kaymaz F, Duruksu G. 2011. Human dental pulp stem cells demonstrate better neural and epithelial stem cell properties than bone marrow-derived
Kitajima S, Miki T, Takegami Y, Kido Y, Noda M, Hara E, Shamma A, Takahashi C. 2011. Reversion-inducing cysteine-rich protein with Kazal motifs interferes with epidermal growth factor receptor signaling. *Oncogene* 30:737-750 DOI: 10.1038/onc.2010.448.

Kuratate M, Yosybiba K, Sbigetani Y, Yoshiba N, Obsbima H, Okiji T. 2008. Immunohistochemical analysis of nestin, osteopontin, and proliferating cells in the reparative process of exposed dental pulp capped with mineral trioxide aggregate. *Journal of Endodontics* 34:970-974 DOI: 10.1016/j.joen.2008.03.021.

Lambiv WL, Vassallo I, Delorenzi M, Shay T, Diserens AC, Misra A, Feuerstein B, Murat A, Migliavacca E, Hamou MF, Sciuscio D, Burger R, Domany E, Stupp R, Hegi ME. 2011. The Wnt inhibitory factor 1 (WIF1) is targeted in glioblastoma and has a tumor suppressing function potentially by induction of senescence. *Neuro-Oncology* 13:736-747 DOI: 10.1093/neuonc/nor036.

Li XD, Ominsky MS, Warmington KS, Morony S, Gong JH, Cao J, Gao YM, Shalhoub V, Tipton B, Haldankar RJ, Chen Q, Winters A, Boone T, Geng ZP, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS, Lacey DL, Paszty C. 2009. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. *Journal of Bone and Mineral Research* 24:578-588 DOI: 10.1359/jbmr.081206.

Loots GG, Kneissel M, Keller H, Baptist M, Chang J, Collette NM, Ovcharenko D, Plajzer-Frick I, Rubin EM. 2005. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. *Genome Research* 15:928-935 DOI: 10.1101/gr.3437105.
Ma DD, Ma ZF, Zhang XJ, Wang WH, Yang ZH, Zhang M, Wu G, Lu W, Deng ZH, Jin Y. 2009. Effect of age and extrinsic microenvironment on the proliferation and osteogenic differentiation of rat dental pulp stem cells in vitro. *Journal of Endodontics* 35:1546-1553 DOI: 10.1016/j.joen.2009.07.016.

Mas-Bargues C, Vina-Almunia J, Ingles M, Sanz-Ros J, Gambini J, Ibanez-Cabellos JS, Garcia-Gimenez JL, Vina J, Borras C. 2017. Role of p16(INK4a) and BMI-1 in oxidative stress-induced premature senescence in human dental pulp stem cells. *Redox Biology* 12:690-698 DOI: 10.1016/j.redox.2017.04.002.

Mehrazarin S, Oh JF, Chung CL, Chen W, Kim RH, Shi ST, Park NH, King MK. 2011. Impaired odontogenic differentiation of senescent dental mesenchymal stem cells is associated with loss of bmi-1 expression. *Journal of Endodontics* 37:662-666 DOI: 10.1016/j.joen.2011.02.009.

Min KS, Lee YM, Hong SO, Kim EC. 2010. Simvastatin promotes odontoblastic differentiation and expression of angiogenic factors via heme oxygenase-1 in primary cultured human dental pulp cells. *Journal of Endodontics* 36:447-452 DOI: 10.1016/j.joen.2009.11.021.

Modder UI, Hoey KA, Amin S, McCready LK, Achenbach SJ, Riggs BL, Melton LJ, Khosla S. 2011. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. *Journal of Bone and Mineral Research* 26:373-379 DOI: 10.1002/jbmr.217.

Modino SAC, Sharpe PT. 2005. Tissue engineering of teeth using adult stem cells. *Archives of Oral Biology* 50:255-258 DOI: 10.1016/j.archoralbio.2005.01.002.

Muthna D, Soukup T, Vavrova J, Mokry J, Cmielova J, Visek B, Jiroutova A, Havelek R, Suchanek J, Filip S, English D, Rezacova M. 2010. Irradiation of adult human dental pulp stem cells provokes activation of p53, cell cycle arrest, and senescence but not apoptosis. *Stem Cells and Development* 19:1855-1862 DOI: 10.1089/scd.2009.0449.
Naka T, Yokose S. 2011. Spatiotemporal expression of sclerostin in odontoblasts during embryonic mouse tooth morphogenesis. *Journal of Endodontics* 37:340-345 DOI: 10.1016/j.joen.2010.11.025.

Nakashima M, Iohara K. 2014. Mobilized dental pulp stem cells for pulp regeneration: initiation of clinical trial. *Journal of Endodontics* 40:S26-32 DOI: 10.1016/j.joen.2014.01.020.

Ota K, Quint P, Ruan M, Pederson L, Westendorf JJ, Khosla S, Oursler MJ. 2013. Sclerostin is expressed in osteoclasts from aged mice and reduces osteoclast-mediated stimulation of mineralization. *Journal of Cellular Biochemistry* 114:1901-1907 DOI: 10.1002/jcb.24537.

Potdar PD, Jethmalani YD. 2015. Human dental pulp stem cells: Applications in future regenerative medicine. *World Journal of Stem Cells* 7:839-851 DOI: 10.4252/wjsc.v7.i5.839.

Rayess H, Wang MB, Srivatsan ES. 2012. Cellular senescence and tumor suppressor gene p16. *International Journal of Cancer* 130:1715-1725 DOI: 10.1002/ijc.27316.

Roforth MM, Fujita K, McGregor UI, Kirmani S, McCready LK, Peterson JM, Drake MT, Monroe DG, Khosla S. 2014. Effects of age on bone mRNA levels of sclerostin and other genes relevant to bone metabolism in humans. *Bone* 59:1-6 DOI: 10.1016/j.bone.2013.10.019.

Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S. 2013. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. *Cell Metabolism* 18:416-430 DOI: 10.1016/j.cmet.2013.07.013.

Semenov M, Tamai K, Xi H. 2005. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. *Journal of Biological Chemistry* 280:26770-26775 DOI: 10.1074/jbc.M504308200.

Simon SR, Berdal A, Cooper PR, Lumley PJ, Tomson PL, Smith AJ. 2011. Dentin-pulp complex regeneration: from lab to clinic. *Advances in Dental Research* 23:340-345 DOI: 10.1155/2012/190561.
Soares DG, Basso FG, Hebling J, Costa CAD. 2015. Effect of hydrogen-peroxide-mediated oxidative stress on human dental pulp cells. *Journal of Dentistry* 43:750-756 DOI: 10.1016/j.jdent.2014.12.006.

Sutherland MK, Geoghegan JC, Yu CP, Turcott E, Skonier JE, Winkler DG, Latham JA. 2004. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. *Bone* 35:828-835 DOI: 10.1016/j.bone.2004.05.023.

Tonnessen-Murray CA, Lozano G, Jackson JG. 2017. The regulation of cellular functions by the p53 protein: cellular senescence. *Cold Spring Harbor Perspectives in Medicine* 7 DOI: 10.1101/cshperspect.a026112.

van Lierop AH, Hamdy NAT, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE. 2011. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. *Journal of Bone and Mineral Research* 26:2804-2811 DOI: 10.1002/jbmr.474.

Wagner W, Horn P, Bork S, Ho AD. 2008. Aging of hematopoietic stem cells is regulated by the stem cell niche. *Experimental Gerontology* 43:974-80 DOI: 10.1016/j.exger.2008.04.007.

World Medical A. 2013. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. *JAMA-Journal of the American Medical Association* 310:2191-2194 DOI: 10.1001/jama.2013.281053.

Ye XF, Zerlanko B, Kennedy A, Banumathy G, Zhang RG, Adams PD. 2007. Downregulation of Wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. *Molecular Cell* 27:183-196 DOI: 10.1016/j.molcel.2007.05.034.
Yen AHH, Sharpe PT. 2006. Regeneration of teeth using stem cell-based tissue engineering. *Expert Opinion on Biological Therapy* 6:9-16 DOI: 10.1517/14712598.6.1.9.

Zhang DD, Park BM, Kang M, Nam H, Kim EJ, Bae C, Lim SK. 2016. The systemic effects of sclerostin overexpression using Phi C31 integrase in mice. *Biochemical and Biophysical Research Communications* 472:471-476 DOI: 10.1016/j.bbrc.2016.01.178.

Zhou H, Yang M, Li M, Cui L. 2017. Radial artery sclerostin expression in chronic kidney disease stage 5 predialysis patients: a cross-sectional observational study. *International Urology and Nephrology* 49:1433-1437 DOI: 10.1007/s11255-017-1604-0.

Zou J, Zhang W, Li XL. 2017. Effects of SOST gene silencing on proliferation, apoptosis, invasion, and migration of human osteosarcoma cells through the Wnt/β-catenin signaling pathway. *Calcified Tissue International* 100:551-564 DOI: 10.1007/s00223-016-0231-6.
Figure 1

Expressions of sclerostin in senescent dental pulp, subculture-induced senescent HDPCs and lentiviral infected HDPCs.

(A) Immunohistochemical staining for sclerostin in young dental pulps; (B) immunohistochemical staining for sclerostin in senescent dental pulps (green arrows point to odontoblasts and red arrows point to dental pulp cells); d, dentin; pd, predentin; p, pulp; ob, odontoblast; scale bar = 20μm. (C) qRT-PCR analyses of expression levels of sclerostin, p16, p53, and p21 in young and senescent dental pulps; (D) qRT-PCR analyses of expression levels of sclerostin, p16, p53, and p21 in subculture-induced senescent HDPCs. (E) qRT-PCR and (F) Western blot analyses of sclerostin expressions in HDPCs infected with control vector and SOST; (G) qRT-PCR and (H) Western blot analyses of sclerostin expression in HDPCs infected with sh-control vector and sh-SOST. (** p < 0.01; *** P < 0.001)
Figure 2

Effects of sclerostin overexpression and knockdown on senescence and proliferation of HDPCs.

(A) SA-β-Gal staining and (B) cell proliferation activity of Control and SOST HDPCs; (C) qRT-PCR analyses of expression levels of p16, p53, and p21 in Control and SOST HDPCs. (D) SA-β-Gal staining and (E) cell proliferation activity of sh-Ctrl and sh-SOST HDPCs; (F) qRT-PCR analyses of expression levels of p16, p53, and p21 in sh-Ctrl and sh-SOST HDPCs. (*p < 0.05, **p < 0.01; ***P < 0.001)
Figure 3

Effects of sclerostin on odontoblastic differentiation of HDPCs.

(A) ALP staining and ALP activity of early-passaged Control and SOST HDPCs on day 7; (B) alizarin red staining for mineral nodule formation of early-passaged Control and SOST HDPCs on day 14; (C) qRT-PCR analyses of expression levels of odontoblastic markers in early-passaged Control and SOST HDPCs on day 7. (D) ALP staining and ALP activity of late-passaged sh-Ctrl and sh-SOST HDPCs on day 7; (E) alizarin red staining for mineral nodule formation of late-passaged sh-Ctrl and sh-SOST HDPCs on day 14; (F) qRT-PCR analyses of odontoblastic markers in late-passaged sh-Ctrl and sh-SOST HDPCs on day 7. (*p <0.05, ** p <0.01; *** P <0.001)
Figure 4

Effect of sclerostin on Wnt/β-catenin pathway.

(A) Western blot analysis of p-β-catenin expression in early-passaged Control and SOST HDPCs; (B) Western blot analysis of p-β-catenin expression in late passaged sh-Ctrl and sh-SOST HDPCs. (*p <0.05, ** p <0.01)
**Table 1** (on next page)

Primer Sequences Used for Real-time PCR.
Table 1 Primer Sequences Used for Real-time PCR

| Genes    | Forward(5'-3') | Reverse(5'-3') |
|----------|---------------|----------------|
| GAPDH    | AACAGCGACACCCACTCCCTC | CATACCAGGAAATGAGCTTGACAA |
| ALP      | CGAGATACAAGCACTCCCATTC | CTGTTCAGCTCGTACTGCATGTC |
| OPN      | GCCGAGGTGATAGTGTGGTT | CAACGGGGATGGCCTTGTAT |
| OCN      | GGTGCAGCTTTGTGTCCAA | CCTGAAAGCCGATGTGGTCA |
| DSPP     | CAACCATAGAGAAAGCAAACCGG | TTTCTGTGTCCTGACTGGGAC |
| Sclerostin | TGGCAGGCCGTTCAAGAATGA | GCCCGGTTTCATGGTCTTTGTT |
| P16      | CCAACGCACCAGAATAGTTAC | CAGCAGCTCGCAGACTC |
| P53      | ACCTATGGAAAATCCTCTGAAA | CTGGCATTTCTGGAGCTTCA |
| P21      | TCAGGGTTCGAAAAACGGCG | CCTTTGGGAGAAGATCAGCCG |